JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Comparison of Lethal Means Counseling and an Active Control Condition, With and Without Provision of Gun Locks

  NCT03375099

  Condition:   Intentional Self-Harm by Other Specified Means
  Interventions:   Behavioral: Lethal Means Counseling;   Behavioral: Health and Stress Reduction
  Sponsors:   University of Southern Mississippi;   University of Utah
  Recruiting
• Pomegranate Supplementation and Well-Being Among Medical Students and Residents

  NCT03063372

  Conditions:   Antioxidant;   Burnout, Professional;   Psychological Distress
  Interventions:   Dietary Supplement: Pomella pomegranate extract;   Other: Placebo
  Sponsors:   University of Mississippi Medical Center;   University of Rhode Island
  Enrolling by invitation
• Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

  NCT02989025

  Condition:   Pregnancy
  Intervention:   Drug: 17 OHPC
  Sponsor:   Babbette Lamarca
  Recruiting
• Sensorimotor Training for Injury Prevention in Collegiate Soccer Players II

  NCT04036916

  Conditions:   Concussion, Mild;   Sport Injury
  Intervention:   Other: Virtual Reality Sensorimotor Training
  Sponsors:   University of Mississippi Medical Center;   University of West Alabama;   Mississippi College
  Not yet recruiting
• Do AxoGuard Implants Decrease Shoulder Disability After Neck Dissections

  NCT03941327

  Conditions:   Spinal Accessory Nerve Injury;   Cervical Lymphadenopathy
  Intervention:   Device: AxoGuard Nerve Cuff
  Sponsor:   University of Mississippi Medical Center
  Recruiting
• Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen

  NCT03934450

  Conditions:   Malaria;   Glucose 6 Phosphate Dehydrogenase Deficiency
  Interventions:   Drug: RPQ;   Drug: SPQ;   Drug: Primaquine Phosphate;   Drug: Placebo
  Sponsor:   University of Mississippi, Oxford
  Completed
• Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

  NCT03876301

  Conditions:   Blood Coagulation Disorder;   Blood Coagulation Disorders, Inherited;   Coagulation Protein Disorders;   Hemophilia A;   Genetic Diseases, Inborn;   Genetic Diseases, X-Linked;   Hematologic Diseases;   Hemorrhagic Disorders;   Factor VIII Deficiency
  Intervention:   Drug: Standard of Care FVIII Replacement therapy
  Sponsor:   Spark Therapeutics
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

  NCT03861273

  Condition:   Hemophilia B
  Intervention:   Biological: PF-06838435/ fidanacogene elaparvovec
  Sponsor:   Pfizer
  Not yet recruiting
• Telemedicine for PrEP Throughout Mississippi

  NCT03840382

  Condition:   HIV/AIDS
  Intervention:   Behavioral: Tele-PrEP Intervention
  Sponsors:   Rhode Island Hospital;   University of Mississippi Medical Center
  Not yet recruiting
• Lower Limb Flexor Synergy Training in Chronic Stroke

  NCT03833544

  Condition:   Stroke
  Intervention:   Other: Exercise training
  Sponsor:   Methodist Rehabilitation Center
  Recruiting
• Pilot of Home Visitation Services for Patients With a Diabetes Diagnosis

  NCT03374098

  Condition:   Diabetes
  Interventions:   Behavioral: Home Visitiation;   Behavioral: Education
  Sponsors:   Delta Health Alliance;   University of Tennessee Health Science Center
  Active, not recruiting
• PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening

  NCT02286713

  Conditions:   Lung Cancer;   Smoking Cessation;   Tobacco Use Cessation
  Interventions:   Behavioral: Patient Decision Aid;   Behavioral: Standard Educational Information;   Behavioral: Follow-Up Assessments: Questionnaires
  Sponsors:   M.D. Anderson Cancer Center;   Patient-Centered Outcomes Research Institute
  Active, not recruiting
• A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome

  NCT02697240

  Condition:   Sickle Cell Disease
  Intervention:   Drug: Intravenous citrulline
  Sponsor:   University of Mississippi Medical Center
  Completed
• Safer Sex Program for Young African-American Men

  NCT01439503

  Conditions:   Gonorrhea;   Chlamydia;   Trichomoniasis;   Syphilis;   HIV Infections
  Intervention:   Behavioral: Intervention
  Sponsors:   Richard Crosby;   National Institute of Mental Health (NIMH)
  Completed
• Levels of Bisphenol A in Urine and Saliva Following Placement of Composite Restorations

  NCT00339339

  Condition:   Dental Restorations
  Intervention:  
  Sponsor:   National Institute of Dental and Craniofacial Research (NIDCR)
  Completed
• LSI (Lesion Index) Workflow Observational Study

  NCT03906461

  Condition:   Paroxysmal Atrial Fibrillation
  Intervention:   Device: Radiofrequency Ablation
  Sponsor:   Abbott Medical Devices
  Recruiting
• Speed of Robotic Leg Movements and Orthostatic Hypotension in Subacute SCI

  NCT04029974

  Conditions:   Spinal Cord Injuries;   Orthostatic Hypotension
  Intervention:   Device: ErigoPro
  Sponsor:   Methodist Rehabilitation Center
  Not yet recruiting
• The Use of an Online Learning and Consent Platform in Infertility Treatment

  NCT03962257

  Condition:   Patient Satisfaction
  Intervention:   Other: EngagedMD online learning platform
  Sponsor:   University of North Carolina, Chapel Hill
  Recruiting
• Electronic Pre-exposure Prophylaxis (PrEP) Initiation and Maintenance Home Care System

  NCT03729570

  Condition:   Pre-exposure Prophylaxis
  Intervention:   Other: ePrEP
  Sponsors:   Emory University;   National Institutes of Health (NIH);   University of North Carolina, Chapel Hill;   University of Mississippi Medical Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)

  NCT03763942

  Condition:   HIV Infections
  Interventions:   Behavioral: HealthMindr App;   Behavioral: Control App
  Sponsors:   Emory University;   National Institutes of Health (NIH);   National Institute on Drug Abuse (NIDA)
  Not yet recruiting
• Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State

  NCT00693121

  Conditions:   Traumatic Brain Injury;   Posttraumatic Confusional State;   Delirium
  Interventions:   Drug: Amantadine hydrochloride;   Drug: Placebo capsule
  Sponsors:   Methodist Rehabilitation Center;   U.S. Department of Education
  Completed
• Trichomoniasis: Genotype and Phenotype Correlations in African American Women

  NCT00998530

  Condition:   Trichomonas Infections
  Intervention:  
  Sponsors:   University of Mississippi Medical Center;   Mississippi State Department of Health
  Completed
• Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

  NCT03734588

  Conditions:   Adeno-Associated Virus (AAV);   Blood Coagulation Disorder;   Blood Coagulation Disorders, Inherited;   Coagulation Protein Disorders;   Factor VIII (FVIII);   Factor VIII (FVIII) Deficiency;   Factor VIII (FVIII) Gene;   Factor VIII (FVIII) Protein;   Genetic Diseases, Inborn;   Genetic Diseases, X-Linked;   Gene Therapy;   Gene Transfer;   Hematologic Diseases;   Hemorrhagic Disorders;   Recombinant;   Vector;   Inhibitors
  Intervention:   Genetic: SPK-8016
  Sponsor:   Spark Therapeutics
  Recruiting
• Treatment of ppROM With Erythromycin vs. Azithromycin Trial

  NCT03060473

  Condition:   Preterm Premature Rupture of Membranes (PPROM)
  Interventions:   Drug: Azithromycin;   Drug: Erythromycin;   Drug: Ampicillin;   Drug: Amoxicillin
  Sponsor:   The University of Texas Medical Branch, Galveston
  Recruiting
• The DETECT HCV Screening Trial

  NCT04003454

  Condition:   Hepatitis C
  Intervention:   Other: HCV Screening
  Sponsors:   Denver Health and Hospital Authority;   Johns Hopkins University;   University of Mississippi Medical Center;   Boston University;   Boston Medical Center;   University of Cincinnati;   Alameda County Medical Center
  Not yet recruiting
• A Mobile Gaming App to Improve ART Adherence for Youth

  NCT03760211

  Conditions:   Medication Adherence;   HIV/AIDS
  Interventions:   Behavioral: Multilevel Gaming Adherence Intervention;   Behavioral: Treatment as Usual +
  Sponsors:   Rhode Island Hospital;   University of Mississippi Medical Center;   Boston Medical Center
  Not yet recruiting
• Postoperative and Chronic Pain Genetic Spine Surgery Study

  NCT02998138

  Conditions:   Scoliosis;   Kyphosis;   Kyphoscoliosis
  Intervention:  
  Sponsor:   Children's Hospital Medical Center, Cincinnati
  Enrolling by invitation
• Hypoxia and Inflammatory Injury in Human Renovascular Hypertension

  NCT02266394

  Conditions:   Renal Artery Stenosis;   Ischemic Nephropathy;   Renovascular Disease;   Chronic Kidney Disease
  Interventions:   Drug: Mesenchymal stem cell;   Procedure: Mesenchymal stem cell delivery with stent placement
  Sponsors:   Mayo Clinic;   University of Mississippi Medical Center;   University of Alabama at Birmingham
  Active, not recruiting
• Pre-exposure Prophylaxis (PrEP) at Home

  NCT03569813

  Condition:   HIV/AIDS
  Interventions:   Behavioral: PrEP@Home System;   Other: Standard of Care
  Sponsors:   Emory University;   National Institute of Mental Health (NIMH)
  Recruiting
• An Investigation of Functional Improvements in the RHEO KNEE Compared to Hydraulic MPKs

  NCT04023578

  Conditions:   Prosthesis User;   Amputation
  Intervention:   Device: RHEO KNEE XC
  Sponsors:   Össur Ehf;   Baker Orthotics & Prosthetics;   Virginia Prosthetics & Orthotics;   Methodist Rehabilitation Center
  Completed
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

  NCT03652077

  Conditions:   Cervical Cancer;   Gastric Cancer;   Stomach Cancer;   Gastroesophageal Junction Cancer;   Esophageal Cancer;   Hepatocellular Carcinoma;   Melanoma;   Uveal Melanoma;   Merkel Cell Carcinoma;   Mesothelioma;   MSI;   Non-small Cell Lung Cancer;   NSCLC;   Ovarian Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   RCC;   Triple-negative Breast Cancer;   Urothelial Carcinoma;   Mismatch Repair Deficiency
  Intervention:   Drug: INCAGN02390
  Sponsor:   Incyte Corporation
  Recruiting
• South-seq: Deoxyribonucleic Acid (DNA) Sequencing for Newborn Nurseries in the South

  NCT03842995

  Condition:   Whole Genome Sequencing
  Interventions:   Behavioral: Genetic Counselor;   Behavioral: Trained Healthcare Provider
  Sponsors:   University of Alabama at Birmingham;   University of Mississippi Medical Center;   HudsonAlpha Institute for Biotechnology;   Woman's Hospital, Louisiana;   Children's Hospital of New Orleans
  Recruiting
• Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force

  NCT03276637

  Conditions:   Healthy Adults;   Genetic Predisposition to Disease
  Intervention:   Genetic: Whole exome sequencing
  Sponsors:   Brigham and Women's Hospital;   United States Department of Defense
  Active, not recruiting
• RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

  NCT03699956

  Condition:   Carcinoma, Small Cell Lung
  Interventions:   Combination Product: RRx-001 + eLOOP Device;   Drug: Cisplatin/carboplatin plus etoposide
  Sponsors:   EpicentRx, Inc.;   Parexel
  Recruiting
• Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

  NCT01931852

  Conditions:   Acute Coronary Syndrome;   Chest Pain
  Interventions:   Procedure: Cardiac MRI;   Other: ACC/AHA Guideline adherent care
  Sponsors:   Wake Forest University Health Sciences;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
  Active, not recruiting
• A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

  NCT03394781

  Condition:   Primary Sclerosing Cholangitis
  Intervention:   Drug: DUR-928
  Sponsor:   Durect
  Terminated
• Epidural Steroid Injection Versus Epidural Steroid Injection and Manual Physical Therapy and Exercise in the Management of Lumbar Spinal Stenosis

  NCT00786981

  Condition:   Lumbar Spinal Stenosis
  Interventions:   Other: Epidural steroid injection plus physical therapy;   Other: Epidural steroid injection
  Sponsors:   Franklin Pierce University;   University of Colorado, Denver
  Completed
• Phase 2B/3 Double-blinded Placebo-controlled

  NCT03107377

  Condition:   Chlamydia Trachomatis Infection
  Interventions:   Drug: Amphora gel;   Drug: Placebo
  Sponsors:   Evofem Inc.;   Clinical Research Management, Inc.
  Active, not recruiting
• Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

  NCT02270814

  Conditions:   Head and Neck Cancer;   Head and Neck Squamous Cell Carcinoma;   Cancer of the Head and Neck
  Interventions:   Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Biological: Cetuximab
  Sponsors:   Washington University School of Medicine;   Celgene Corporation
  Recruiting
• Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems

  NCT02475200

  Conditions:   Peripheral Arterial Disease;   Claudication;   Critical Limb Ischemia
  Intervention:   Device: Atherectomy
  Sponsor:   Volcano Corporation
  Enrolling by invitation
• Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer

  NCT03499353

  Condition:   Early Breast Cancer
  Intervention:   Drug: TALAZOPARIB
  Sponsor:   Pfizer
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   PD-L1 Positive;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

  NCT03418961

  Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928

  Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
  Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Tele-Exercise and Multiple Sclerosis

  NCT03117881

  Condition:   Multiple Sclerosis
  Interventions:   Behavioral: DirectCAM;   Behavioral: TeleCAM
  Sponsors:   University of Alabama at Birmingham;   Patient-Centered Outcomes Research Institute;   Lakeshore Foundation;   Tanner Foundation for Neurological Diseases
  Recruiting
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

  NCT03087708

  Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
  Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

  NCT02785913

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Taselisib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944

  Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Intervention:   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905

  Conditions:   Breast Carcinoma Metastatic in the Brain;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

  NCT02856581

  Condition:   Lung Carcinoma
  Interventions:   Drug: Varenicline;   Drug: Placebo;   Other: Tobacco Cessation Counseling
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Pfizer
  Recruiting
• S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

  NCT02728804

  Conditions:   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
  Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

  NCT02562716

  Conditions:   Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma
  Interventions:   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Procedure: Pancreatectomy
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Positive;   HER2/Neu Negative;   Locally Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin;   Drug: Goserelin Acetate;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

  NCT02728596

  Conditions:   Febrile Neutropenia;   Stage 0 Breast Cancer;   Stage 0 Colorectal Cancer;   Stage 0 Non-Small Cell Lung Cancer;   Stage I Colorectal Cancer;   Stage IA Breast Cancer;   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Breast Cancer;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Breast Cancer;   Stage IIA Colorectal Cancer;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Breast Cancer;   Stage IIB Colorectal Cancer;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIC Colorectal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
  Interventions:   Other: Preventive Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Patient-Centered Outcomes Research Institute
  Recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

  NCT04027387

  Condition:   HIV-1-infection
  Intervention:   Biological: TMB-365
  Sponsors:   TaiMed Biologics Inc.;   Westat
  Not yet recruiting
• S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881

  Condition:   Colorectal Neoplasms
  Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
  Recruiting
• Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

  NCT01953588

  Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
  Interventions:   Drug: fulvestrant;   Drug: anastrozole
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia

  NCT03654768

  Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

  NCT02997228

  Conditions:   Colorectal Adenocarcinoma;   Mismatch Repair Deficiency;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

  NCT02921256

  Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
  Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

  NCT02822573

  Conditions:   Cognitive Dysfunction;   Memory Impairment
  Interventions:   Drug: Donepezil 5 mg;   Drug: Placebo
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

  NCT01275677

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
  Interventions:   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

  NCT01272037

  Conditions:   Ductal Breast Carcinoma In Situ;   Estrogen Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Progesterone Receptor Positive;   Synchronous Bilateral Breast Carcinoma
  Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853

  Condition:   Lung Cancer
  Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects

  NCT02273726

  Condition:   CKD Anemia in Stable Dialysis Patients
  Interventions:   Drug: Epoetin Alfa;   Drug: FG-4592
  Sponsors:   FibroGen;   Astellas Pharma Europe B.V.;   AstraZeneca
  Completed
• GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

  NCT00373685

  Condition:   Osteoarthritis
  Interventions:   Drug: Celecoxib;   Drug: Any commercially available NSAID with the indication for osteoarthritis
  Sponsor:   Pfizer
  Completed
• Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients

  NCT02052310

  Condition:   Anemia in Incident Dialysis Patients
  Interventions:   Drug: FG-4592 (roxadustat);   Drug: Epoetin Alfa
  Sponsors:   FibroGen;   Astellas Pharma Europe B.V.;   AstraZeneca
  Completed
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

  NCT00769379

  Conditions:   Ductal Breast Carcinoma In Situ;   HER2/Neu Positive
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

  NCT01785875

  Condition:   Hyperparathyroidism, Secondary
  Intervention:   Drug: Etelcalcetide
  Sponsor:   Amgen
  Completed
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

  NCT00310180

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIB Breast Cancer AJCC v7
  Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
  Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

  NCT01674140

  Condition:   Breast Cancer
  Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Cardiovascular Inflammation Reduction Trial

  NCT01594333

  Condition:   Cardiovascular Disease
  Interventions:   Drug: Methotrexate;   Drug: Placebo
  Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
  Completed
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805

  Conditions:   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pemetrexed Disodium;   Other: Questionnaire Administration;   Drug: Vinorelbine Tartrate
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737

  Conditions:   Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer AJCC v7;   Stage IIB Colon Cancer AJCC v7;   Stage IIC Colon Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

  NCT03439254

  Conditions:   Compensated Cirrhosis;   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Obeticholic acid (10 mg);   Drug: Obeticholic acid (10 mg to 25 mg);   Drug: Placebo
  Sponsor:   Intercept Pharmaceuticals
  Recruiting
• Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561

  Conditions:   Extensive Stage Lung Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

  NCT02887183

  Condition:   Heart Failure
  Intervention:   Drug: LCZ696 (sacubitril/valsartan)
  Sponsor:   Novartis Pharmaceuticals
  Completed
• Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

  NCT00063999

  Conditions:   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• A Phase 3 Study of Tanezumab for Chronic Low Back Pain

  NCT02528253

  Condition:   Low Back Pain
  Interventions:   Biological: Placebo to Week 16; tanezumab 5mg SC;   Biological: Placebo to Week 16, tanezumab 10 mg SC;   Biological: Tanezumab 5 mg SC;   Biological: Tanezumab 10 mg SC;   Biological: Tramadol PR oral
  Sponsors:   Pfizer;   Eli Lilly and Company
  Completed
• Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

  NCT02217475

  Condition:   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Cenicriviroc;   Drug: Placebo
  Sponsor:   Tobira Therapeutics, Inc.
  Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

  NCT01920711

  Condition:   Heart Failure With Preserved Ejection Fraction
  Interventions:   Drug: LCZ696;   Drug: Valsartan
  Sponsor:   Novartis Pharmaceuticals
  Completed
• Advance Cardiac Resynchronization Therapy (CRT) Registry

  NCT01805154

  Condition:   Heart Failure
  Intervention:   Device: CRT Patients
  Sponsor:   Abbott Medical Devices
  Completed
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

  NCT01306890

  Conditions:   Advanced Prostate Cancer;   Prostatic Neoplasms
  Intervention:   Biological: sipuleucel-T
  Sponsor:   Dendreon
  Completed
• Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

  NCT01057693

  Condition:   Diabetic Neuropathy, Painful
  Interventions:   Drug: pregabalin (Lyrica);   Drug: Placebo
  Sponsor:   Pfizer
  Completed
• Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

  NCT01015833

  Conditions:   Advanced Adult Hepatocellular Carcinoma;   Recurrent Hepatocellular Carcinoma;   Stage III Hepatocellular Carcinoma AJCC v7;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Hepatocellular Carcinoma AJCC v7;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVB Hepatocellular Carcinoma AJCC v7;   Unresectable Hepatocellular Carcinoma
  Interventions:   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Drug: Sorafenib Tosylate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

  NCT00977574

  Conditions:   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Temsirolimus
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

  NCT00946712

  Conditions:   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Large Cell Lung Carcinoma;   Stage IV Lung Adenocarcinoma;   Stage IV Squamous Cell Lung Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

  NCT00942331

  Conditions:   Advanced Urothelial Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Prostate Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Metastatic Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Prostate Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Unresectable Urothelial Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

  NCT00693992

  Conditions:   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IV Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sunitinib Malate
  Sponsor:   National Cancer Institute (NCI)
  Completed
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228

  Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
  Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

  NCT00565851

  Conditions:   Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

  NCT00490139

  Condition:   Neoplasms, Breast
  Interventions:   Drug: Lapatinib;   Biological: Trastuzumab
  Sponsors:   Novartis Pharmaceuticals;   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Breast International Group;   Canadian Cancer Trials Group
  Active, not recruiting
• An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

  NCT00791700

  Condition:   Human Immunodeficiency Virus
  Intervention:   Drug: Maraviroc
  Sponsors:   ViiV Healthcare;   Pfizer
  Active, not recruiting
• A Phase 2b Study of Icosabutate in Fatty Liver Disease

  NCT04052516

  Condition:   Non Alcoholic Steatohepatitis (NASH)
  Interventions:   Drug: Icosabutate;   Drug: Placebo
  Sponsor:   NorthSea Therapeutics B.V.
  Recruiting
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474

  Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

  NCT03912532

  Condition:   NASH - Nonalcoholic Steatohepatitis
  Interventions:   Biological: NGM282;   Other: Placebo
  Sponsor:   NGM Biopharmaceuticals, Inc
  Recruiting
• Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer

  NCT03793166

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
  Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

  NCT03777059

  Condition:   Episodic Migraine
  Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo;   Drug: Atogepant 10 mg
  Sponsor:   Allergan
  Recruiting
• Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

  NCT03698019

  Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.

  NCT03682705

  Condition:   Rheumatoid Arthritis (RA)
  Interventions:   Drug: Upadacitinib;   Drug: ABBV-105;   Drug: Upadacitinib placebo;   Drug: ABBV-105 placebo
  Sponsor:   AbbVie
  Recruiting
• Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

  NCT01146561

  Condition:   Chronic Pancreatitis
  Interventions:   Biological: Tanezumab;   Other: Placebo
  Sponsor:   Pfizer
  Terminated
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

  NCT03662204

  Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
  Intervention:   Other: Blood Sample Collection
  Sponsor:   Exact Sciences Corporation
  Recruiting
• An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION]

  NCT03616821

  Conditions:   Colitis;   Ulcerative;   IBD
  Interventions:   Drug: Brazikumab;   Drug: Vedolizumab;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

  NCT03602560

  Condition:   Primary Biliary Cholangitis
  Interventions:   Drug: seladelpar 5-10 mg;   Drug: seladelpar 10 mg;   Drug: Placebo
  Sponsor:   CymaBay Therapeutics, Inc.
  Recruiting
• An Investigational Study of Experimental Medication BMS-986165 in Patients With Moderate to Severe Crohn's Disease

  NCT03599622

  Conditions:   Granulomatous Colitis;   Crohn's Disease;   Crohn's Enteritis;   Granulomatous Enteritis
  Interventions:   Drug: BMS-986165;   Other: Placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

  NCT03598257

  Condition:   Inflammatory Breast Carcinoma
  Interventions:   Drug: Olaparib;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

  NCT03594058

  Condition:   Overactive Bladder
  Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo
  Sponsor:   Velicept Therapeutics, Inc.
  Active, not recruiting
• Efficacy and Safety of Intravenous Neridronic Acid in CRPS

  NCT03530345

  Condition:   Complex Regional Pain Syndrome (CRPS)
  Interventions:   Drug: Neridronic acid;   Drug: Placebo
  Sponsor:   Grünenthal GmbH
  Terminated
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

  NCT03444870

  Condition:   Alzheimer Disease
  Interventions:   Drug: Gantenerumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

  NCT03428217

  Conditions:   Advanced Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
  Interventions:   Drug: CB-839;   Drug: Cabozantinib;   Drug: Placebo
  Sponsor:   Calithera Biosciences, Inc
  Recruiting
• A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

  NCT03422653

  Condition:   Uremic Pruritus
  Interventions:   Drug: CR845 0.5 mcg/kg;   Drug: Placebo
  Sponsor:   Cara Therapeutics, Inc.
  Active, not recruiting
• A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

  NCT03398005

  Condition:   Hypertriglyceridemia
  Interventions:   Drug: CaPre;   Drug: Placebo
  Sponsor:   Acasti Pharma Inc.
  Active, not recruiting
• A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

  NCT03345849

  Condition:   Crohn's Disease
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

  NCT03345836

  Condition:   Crohn's Disease
  Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
  Sponsor:   AbbVie
  Recruiting
• Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

  NCT03326674

  Condition:   Breast Cancer
  Interventions:   Drug: Tesetaxel and Capecitabine;   Drug: Capecitabine
  Sponsor:   Odonate Therapeutics, Inc.
  Recruiting
• Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

  NCT03325556

  Condition:   Dementia-related Psychosis
  Interventions:   Drug: Placebo;   Drug: Pimavanserin 34 mg;   Drug: Pimavanserin 20 mg
  Sponsor:   ACADIA Pharmaceuticals Inc.
  Recruiting
• Antibiotic Prophylaxis in Patients Undergoing Elective TKA- Multi-center Trial

  NCT03283878

  Conditions:   Arthropathy of Knee;   Antibiotic Prophylaxis
  Intervention:   Drug: Cefazolin
  Sponsors:   Duke University;   American Association of Hip and Knee Society
  Recruiting
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

  NCT03248882

  Conditions:   Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Placebo;   Drug: PF-05221304
  Sponsor:   Pfizer
  Completed
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

  NCT03114657

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Crenezumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Completed
• Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

  NCT03108456

  Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
  Interventions:   Device: Orbital Atherectomy;   Device: Balloon
  Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
  Recruiting
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674

  Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Untreated Adult Acute Myeloid Leukemia
  Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

  NCT03059446

  Conditions:   Nonalcoholic Steatohepatitis;   Liver Cirrhosis;   Non-alcoholic Fatty Liver Disease
  Intervention:   Drug: Cenicriviroc
  Sponsor:   Tobira Therapeutics, Inc.
  Enrolling by invitation
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

  NCT03055013

  Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Oligometastasis;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
  Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT03038100

  Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
  Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Atezolizumab Placebo
  Sponsors:   Hoffmann-La Roche;   GOG Foundation;   European Network of Gynaecological Oncological Trial Groups (ENGOT)
  Active, not recruiting
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308

  Condition:   RheumatoId Arthritis
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
  Sponsors:   Gilead Sciences;   Galapagos NV
  Active, not recruiting
• Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

  NCT02992132

  Condition:   Agitation and Aggression in Alzheimer's Disease
  Interventions:   Drug: Pimavanserin 34 mg;   Drug: Pimavanserin 20 mg;   Other: Placebo
  Sponsor:   ACADIA Pharmaceuticals Inc.
  Terminated
• Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

  NCT02929329

  Condition:   Heart Failure
  Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
  Sponsors:   Amgen;   Cytokinetics;   Servier
  Active, not recruiting
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

  NCT02924727

  Condition:   Acute Myocardial Infarction
  Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

  NCT02890355

  Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
  Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

  NCT02889796

  Condition:   Rheumatoid Arthritis
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib;   Drug: Adalimumab;   Drug: Placebo to match adalimumab;   Drug: MTX
  Sponsors:   Gilead Sciences;   Galapagos NV
  Completed
• Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

  NCT02886728

  Condition:   Rheumatoid Arthritis
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib;   Drug: MTX;   Drug: Placebo to match MTX
  Sponsors:   Gilead Sciences;   Galapagos NV
  Completed
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

  NCT02879305

  Condition:   Anaemia
  Interventions:   Drug: Daprodustat;   Drug: rhEPO;   Drug: Placebo;   Drug: Iron therapy
  Sponsor:   GlaxoSmithKline
  Active, not recruiting
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

  NCT02876835

  Condition:   Anaemia
  Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
  Sponsor:   GlaxoSmithKline
  Recruiting
• Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

  NCT02873936

  Condition:   Rheumatoid Arthritis
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib;   Drug: csDMARDs
  Sponsors:   Gilead Sciences;   Galapagos NV
  Completed
• A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT02763319

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)
  Sponsors:   MorphoSys AG;   ICON Clinical Research
  Recruiting
• Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

  NCT02730377

  Conditions:   Diabetes;   Diabetes Mellitus, Type 2
  Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulphonylurea;   Drug: thiazolidinediones
  Sponsor:   Novo Nordisk A/S
  Active, not recruiting
• Long Term Safety Study of Plecanatide

  NCT02706483

  Condition:   Irritable Bowel Syndrome
  Intervention:   Drug: Plecanatide
  Sponsor:   Bausch Health Americas, Inc.
  Completed
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

  NCT02704403

  Condition:   Nonalcoholic Steatohepatitis (NASH) With Fibrosis
  Interventions:   Drug: Elafibranor;   Drug: Placebo
  Sponsor:   Genfit
  Recruiting
• A Gene Therapy Study for Hemophilia B

  NCT02484092

  Condition:   Hemophilia B
  Intervention:   Biological: SPK-9001
  Sponsor:   Pfizer
  Active, not recruiting
• Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

  NCT02615002

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Piromelatine;   Drug: Placebo
  Sponsor:   Neurim Pharmaceuticals Ltd.
  Active, not recruiting
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

  NCT02574078

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Drug: Nivolumab;   Drug: Bevacizumab;   Drug: Pemetrexed;   Other: Best Supportive Care;   Drug: nab-Paclitaxel;   Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Erlotinib;   Drug: Crizotinib;   Drug: Carboplatin
  Sponsor:   Bristol-Myers Squibb
  Active, not recruiting
• Comparison of Saocubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode.

  NCT02554890

  Condition:   Acute Heart Failure
  Interventions:   Drug: sacubitril/valsartan (LCZ696);   Drug: Enalapril;   Drug: sacubitril/valsartan (LCZ696) matching placebo;   Drug: enalapril matching placebo
  Sponsor:   Novartis Pharmaceuticals
  Completed
• Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

  NCT02528188

  Conditions:   Chronic Pain;   Osteoarthritis, Hip;   Osteoarthritis, Knee
  Interventions:   Drug: NSAID;   Biological: Tanezumab 2.5 mg;   Biological: Tanezumab 5 mg
  Sponsor:   Pfizer
  Completed
• Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

  NCT02504216

  Condition:   Peripheral Artery Disease
  Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
  Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
  Active, not recruiting
• Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02446600

  Conditions:   BRCA Rearrangement;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   AstraZeneca;   NRG Oncology
  Active, not recruiting
• SPYRAL HTN-ON MED Study

  NCT02439775

  Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
  Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
  Sponsor:   Medtronic Vascular
  Recruiting
• SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

  NCT02439749

  Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
  Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
  Sponsor:   Medtronic Vascular
  Recruiting
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT02367781

  Condition:   Carcinoma, Non-Squamous Non-Small Cell Lung
  Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody;   Drug: Carboplatin;   Drug: Nab-Paclitaxel;   Drug: Pemetrexed
  Sponsor:   Hoffmann-La Roche
  Active, not recruiting
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

  NCT02311933

  Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Optisure Lead Post Approval Study

  NCT02235545

  Conditions:   Heart Failure;   Tachycardia, Ventricular
  Intervention:   Device: St. Jude Medical Optisure Lead
  Sponsor:   Abbott Medical Devices
  Active, not recruiting
• Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

  NCT02228681

  Condition:   Advanced, Persistent, or Recurrent Endometrial Cancer
  Interventions:   Drug: Everolimus;   Drug: Tamoxifen;   Drug: Letrozole;   Drug: Medroxyprogesterone Acetate
  Sponsors:   Gynecologic Oncology Group;   Novartis Pharmaceuticals
  Active, not recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   BRAF NP_004324.2:p.V600X;   Metastatic Melanoma;   Progressive Disease;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

  NCT02196181

  Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

  NCT02155660

  Condition:   Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  Interventions:   Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Benralizumab Arm C;   Drug: Placebo
  Sponsors:   AstraZeneca;   MedImmune LLC
  Completed
• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

  NCT02104817

  Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
  Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
  Sponsors:   AstraZeneca;   The Cleveland Clinic;   Quintiles, Inc.
  Active, not recruiting
• Mild and Rapidly Improving Stroke Study

  NCT02072681

  Condition:   Ischemic Stroke
  Intervention:  
  Sponsors:   University of Miami;   American Heart Association
  Active, not recruiting
• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

  NCT02065687

  Conditions:   Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage III Uterine Corpus Cancer AJCC v7;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

  NCT02063672

  Conditions:   Femoral Artery Stenosis;   Femoral Artery Occlusion;   Restenosis
  Interventions:   Device: Lutonix DCB;   Device: Standard Uncoated Balloon Angioplasty Catheter
  Sponsor:   C. R. Bard
  Completed
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

  NCT02019264

  Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
  Interventions:   Drug: Lorcaserin hydrochloride;   Drug: Placebo
  Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
  Completed
• 12-Week Study of Plecanatide for CIC (The CIC3 Study)

  NCT01982240

  Condition:   Chronic Idiopathic Constipation
  Interventions:   Drug: Plecanatide;   Drug: Placebo;   Drug: Bisacodyl
  Sponsor:   Synergy Pharmaceuticals Inc.
  Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

  NCT01975389

  Condition:   Cardiovascular Disease
  Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
  Sponsor:   Pfizer
  Terminated
• A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

  NCT01946204

  Condition:   Prostatic Neoplasms
  Interventions:   Drug: Apalutamide;   Drug: Placebo
  Sponsor:   Aragon Pharmaceuticals, Inc.
  Active, not recruiting
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

  NCT01945775

  Conditions:   Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
  Interventions:   Drug: talazoparib;   Drug: Physician's-Choice
  Sponsors:   Pfizer;   Medivation, Inc.
  Active, not recruiting
• Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

  NCT01919697

  Condition:   Chronic Idiopathic Constipation
  Intervention:   Drug: Plecanatide
  Sponsors:   Bausch Health Americas, Inc.;   Syneos Health
  Completed
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453

  Condition:   Melanoma
  Interventions:   Drug: LGX818;   Drug: MEK162;   Drug: vemurafenib
  Sponsor:   Array BioPharma
  Active, not recruiting
• Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

  NCT01896232

  Conditions:   Secondary Hyperparathyroidism;   Chronic Kidney Disease
  Interventions:   Drug: Etelcalcetide;   Drug: Cinacalcet;   Drug: Oral Placebo;   Drug: Intravenous Placebo
  Sponsor:   Amgen
  Completed
• Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

  NCT01854918

  Condition:   Hyperlipidemia and Mixed Dyslipidemia
  Interventions:   Biological: Evolocumab;   Drug: Standard of Care
  Sponsor:   Amgen
  Completed
• A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427

  Condition:   Breast Neoplasms
  Interventions:   Drug: PD-0332991;   Drug: Letrozole;   Drug: Placebo
  Sponsor:   Pfizer
  Active, not recruiting
• Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry

  NCT01729455

  Condition:   Systemic Lupus Erythematosus
  Interventions:   Biological: BENLYSTA;   Other: SLE treatment
  Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
  Recruiting
• The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

  NCT01722318

  Condition:   Irritable Bowel Syndrome Characterized by Constipation
  Interventions:   Drug: Plecanatide;   Drug: Placebo
  Sponsor:   Bausch Health Americas, Inc.
  Completed
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

  NCT01622868

  Conditions:   ERBB2 Gene Amplification;   HER2 Positive Breast Carcinoma;   Invasive Breast Carcinoma;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Radiation: Stereotactic Radiosurgery;   Radiation: Whole-Brain Radiotherapy
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

  NCT01609790

  Conditions:   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Oligodendroglioma;   Recurrent Brain Neoplasm;   Recurrent Glioblastoma
  Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Biological: Trebananib
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

  NCT01597193

  Condition:   Breast Cancer
  Interventions:   Drug: enzalutamide;   Drug: anastrozole;   Drug: exemestane;   Drug: fulvestrant
  Sponsors:   Pfizer;   Astellas Pharma Inc;   Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
  Completed
• S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

  NCT01498289

  Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
  Interventions:   Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.

  NCT01492361

  Condition:   Cardiovascular Diseases
  Interventions:   Drug: AMR101;   Drug: Placebo
  Sponsor:   Amarin Pharma Inc.
  Completed
• GLORIA-AF Registry Program - Second and Third Phases

  NCT01468701

  Conditions:   Stroke;   Atrial Fibrillation
  Intervention:  
  Sponsor:   Boehringer Ingelheim
  Active, not recruiting
• Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

  NCT01281852

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Recurrent Cervical Carcinoma;   Stage IVB Cervical Cancer AJCC v6 and v7
  Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Veliparib
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Completed
• Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

  NCT01372787

  Conditions:   Anxiety;   Fatigue;   Nausea and Vomiting;   Neurotoxicity Syndrome;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage I Ovarian Cancer AJCC v6 and v7;   Stage IA Fallopian Tube Cancer AJCC v6 and v7;   Stage IB Fallopian Tube Cancer AJCC v6 and v7;   Stage IC Fallopian Tube Cancer AJCC v6 and v7;   Stage II Ovarian Cancer AJCC v6 and v7;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage III Ovarian Cancer AJCC v6 and v7;   Stage III Primary Peritoneal Cancer AJCC v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
  Interventions:   Procedure: Assessment of Therapy Complications;   Other: Medical Chart Review;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

  NCT01369355

  Conditions:   Crohn's Disease;   Colitis;   IBD;   Inflammatory Bowel Disease
  Interventions:   Drug: Placebo SC;   Drug: Placebo IV;   Drug: Ustekinumab 90 mg SC q8w;   Drug: Ustekinumab 130 mg IV;   Drug: Ustekinumab 90 mg SC q12w
  Sponsor:   Janssen Research & Development, LLC
  Active, not recruiting
• Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

  NCT01368588

  Condition:   Prostate Cancer
  Interventions:   Radiation: radiation therapy;   Radiation: Whole-pelvic radiotherapy (WPRT)
  Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

  NCT01333033

  Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
  Interventions:   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Radiation: Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

  NCT01305213

  Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Fosbretabulin Tromethamine;   Other: Laboratory Biomarker Analysis
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Completed
• Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

  NCT01196390

  Conditions:   Esophageal Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   HER2/Neu Positive;   Stage IB Esophageal Cancer AJCC v7;   Stage IIA Esophageal Cancer AJCC v7;   Stage IIB Esophageal Cancer AJCC v7;   Stage IIIA Esophageal Cancer AJCC v7;   Stage IIIB Esophageal Cancer AJCC v7
  Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• QuickFlex Micro Left Ventricular Lead Post Approval Study

  NCT01179477

  Condition:   Heart Failure
  Intervention:   Device: Implantation of a QuickFlex® μ Model 1258T LV Lead
  Sponsor:   Abbott Medical Devices
  Completed
• Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712

  Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Procedure: Computed Tomography;   Drug: Paclitaxel;   Procedure: Therapeutic Conventional Surgery
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting